Document:

Exhibit

PERFORMANCE VESTING
LTIP UNIT AGREEMENT
(2015 Stock Award and Incentive Plan)

This PERFORMANCE VESTING LTIP UNIT AGREEMENT, dated as of [_______] (the “Agreement”), by and between Apartment Investment and Management Company, a Maryland corporation (the “Company”), and [_______] (the “Recipient”). Capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings set forth in the Apartment Investment and Management Company 2015 Stock Award and Incentive Plan, as amended (the “Plan”).

WHEREAS, effective [_______] (the “Date of Grant”), pursuant to the Plan and the Partnership Agreement the Compensation and Human Resources Committee (the “Committee”) of the Board of Directors (the “Board”) of the Company granted the Recipient this LTIP Unit Award and hereby causes the Partnership to issue to the Recipient the maximum number of LTIP Units set forth below, having the rights, restrictions, limitations as to distributions, qualifications and terms and conditions of redemption and conversion set forth herein, in the Plan and in the Partnership Agreement.

NOW, THEREFORE, in consideration of the Recipient’s services to the Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.    Number of LTIP Units.  The Company hereby grants the Recipient an LTIP Unit Award (the “LTIP Award”) with a target of [_______] LTIP Units (the “Restricted LTIP Units”) pursuant to the terms of this Agreement, the provisions of the Plan and the provisions of the Partnership Agreement.  The target number of LTIP Units subject to this LTIP Award (the “Target Award”) was determined by dividing $[__________] by $[_____], which was the average closing price of Aimco’s Common Stock on the New York Stock Exchange for the five trading days up to and including the Date of Grant.  The Recipient may ultimately vest into more LTIP Units or fewer or no LTIP Units, as set forth in more detail in this Agreement.  The Recipient shall be admitted as a partner of the Partnership with beneficial ownership of the Restricted LTIP Units as of the Grant Date by (i) signing and delivering to the Partnership a copy of this Agreement and (ii) signing, as a limited partner, and delivering to the Partnership a counterpart signature page to the Partnership Agreement (attached hereto as Exhibit A).  

2.    Restrictions and Restricted Period. 

(a)    Restrictions.  LTIP Units granted hereunder may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of and shall be subject to a risk of forfeiture until the lapse of the Restricted Period (as defined below).  Neither the Company nor the Partnership shall be required (i) to transfer on its books any LTIP Units which shall have been sold or transferred in violation of any of the provisions set forth in this Agreement, or (ii) to treat as owner of such 

1

LTIP Units or to accord the right to vote as such owner or to pay dividends to any transferee to whom such LTIP Units shall have been so transferred.

(b)    Lapse of Restrictions; Restricted Period.  The restrictions set forth above shall lapse and the Restricted LTIP Units shall become freely transferable (provided, that such transfer is otherwise in accordance with federal and state securities laws) and non-forfeitable as set forth in this Section 2(b) and on Exhibit B.  

(i)    The Company’s total shareholder return (as defined in more detail on Exhibit B, “TSR”) over the period beginning on [_______] and ending on [_______] (the “Performance Period”), as calculated by comparison to the indices stipulated on Exhibit B to this Agreement (and using the methodology set forth on such Exhibit B), shall be compared to the threshold, target and maximum TSR hurdles set forth on Exhibit B to determine the “Vesting Portion” (as defined on Exhibit B) of the LTIP Award as a percentage of the Target Award.  Such calculations shall be determined by the Committee no later than [_______] (the date of such determination, the “Determination Date”).  Restrictions with respect to [__]% of the related Vesting Portion of the LTIP Award set forth on Exhibit B shall lapse as of the later of the Determination Date and the [_______] anniversary of the Date of Grant (the “Vesting Date”), with the restrictions on the remaining [__]% of such Vesting Portion lapsing on the [_______] anniversary of the Date of Grant (the “Anniversary Date”).  

(ii)    Except as set forth in Section 3, each such lapse of restrictions shall occur only if the Recipient has remained employed by the Company through the Vesting Date or the Anniversary Date, as the case may be (the “Restricted Period”).  The portion of the Restricted LTIP Units which does not vest as of the Vesting Date (or the Anniversary Date, as the case may be) based on TSR performance shall be forfeited to the Company without payment of any consideration by the Company, and neither the Recipient nor any of his or her successors, heirs, assigns or personal representatives shall thereafter have any further rights or interests in such shares of Restricted LTIP Units.  

(iii)    All determinations with respect to the calculations pursuant to this Agreement shall be made in the sole discretion of the Committee.  

(c)    Distributions.  

(i)    For purposes of this Agreement, the “Distribution Participation Date” with respect to LTIP Units granted hereunder that have vested in accordance with Section 2(b) hereof shall be the Vesting Date or Anniversary Date, as the case may be.  Such vested LTIP Units shall be entitled to receive the full distribution payable on Partnership Common Units outstanding as of the record date next following the date set forth in the preceding sentence, whether or not they will have been outstanding for the whole period.

2

(ii)    From and after the Date of Grant and prior to the applicable Distribution Participation Date, the Recipient shall be entitled to receive distributions with respect to such Restricted LTIP Units in accordance with the terms of the Partnership Agreement; provided, that the Recipient’s Sharing Percentage for purposes of the Partnership Agreement shall be [___]% (the “Current Distributions”).

(iii)    An amount equal to (i) the difference between (x) all distributions paid with respect to one Partnership Common Unit between the date of grant of an LTIP Unit granted hereunder and the applicable Distribution Participation Date of such LTIP Unit and (y) the Current Distributions paid with respect to such LTIP Unit up to the Distribution Participation Date of such LTIP Unit (such difference, the “Contingent Distributions”) multiplied by (ii) the number of LTIP Units granted hereunder with the same LTIP Unit Distribution Participation Date shall be credited to a notional (unfunded) account for the benefit of the Recipient on the books and records of the Partnership subject to vesting. As promptly as practicable after the applicable Distribution Participation Date, an amount equal to the Contingent Distributions that would have been paid with respect to such LTIP Units that have become vested pursuant to Section 2(b) hereof shall be paid to the Recipient. Any portion of the notional account that is not payable to the Recipient shall be forfeited and revert to the Partnership free and clear of any claims by the Recipient.

(iv)    To the extent that the Partnership makes distributions to holders of Partnership Common Units partially in cash and partially in additional Partnership Common Units or other securities, unless the Administrator in its sole discretion determines to allow the Recipient to make a different election, the Recipient shall be deemed to have elected with respect to all LTIP Units eligible to receive such distribution to receive [___]% of such distribution in cash and [___]% in Partnership Common Units or other securities, with the cash component constituting the Current Distribution prior to the Distribution Participation Date.

3.    Termination of Employment.  Except as otherwise set forth in this Agreement, in the event that the Recipient ceases to be employed by the Company for any reason prior to the lapse of the Restricted Period, then the Restricted LTIP Units shall be forfeited to the Company without payment of any consideration by the Company, and neither the Recipient nor any of his or her successors, heirs, assigns or personal representatives shall thereafter have any further rights or interests in such Restricted LTIP Units.  In the event that the Recipient’s employment with the Company is terminated due to his death or total and permanent disability, then the Restricted Period set forth in Section 2(b) hereof shall immediately lapse and the Restricted LTIP Units shall become immediately and fully vested, with the level of TSR performance calculated as if the date of termination was the final day of the Performance Period, and as if the level of TSR performance as of such date was the higher of (a) target or (b) actual TSR performance as of such date, as determined in the sole discretion of the Committee in accordance with Section 2(b) and Exhibit B.  Restricted LTIP Units not vesting in accordance with the foregoing sentence shall be forfeited to the Company without payment of any consideration by the Company, and neither the Recipient nor any of his or 

3

her successors, heirs, assigns or personal representatives shall thereafter have any further rights or interests in such Restricted LTIP Units.  For purposes of this Section 3, the Recipient’s employment will have terminated by reason of total and permanent disability if, in the reasonable and good faith judgment of the Committee, the Recipient is totally and permanently disabled and is unable to return to or perform his or her duties on a full-time basis.

4.    Change in Control.  The Restricted LTIP Units issued hereunder shall, in addition to any provisions relating to vesting contained in this Agreement, become immediately and fully vested, and the Restricted Period set forth in Section 2(b) hereof shall immediately lapse, upon the termination of the Recipient’s employment with the Company by the Company without Cause or by the Recipient for Good Reason, in either case within twelve (12) months following the occurrence of a Change in Control (as defined below), with the level of TSR performance calculated as if the date of the Change in Control was the final day of the Performance Period, and as if the level of TSR performance as of such date was the higher of (a) target or (b) actual TSR performance as of such date, as determined in the sole discretion of the Committee in accordance with Section 2(b) and Exhibit B.  

(a)    For purposes of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

(i)    an acquisition (other than directly from the Company) of any voting securities of the Company (the “Voting Securities”) by any “person” (as the term “person” is used for purposes of Section 13(d) or Section 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) immediately after which such person has “beneficial ownership” (within the meaning of Rule 13d‐3 promulgated under the Exchange Act) (“Beneficial Ownership”) of 50% or more of the combined voting power of the Company’s then outstanding Voting Securities; provided, however, in determining whether a Change in Control has occurred, the acquisition of Voting Securities in a Non-Control Acquisition (as hereinafter defined) shall not constitute an acquisition that would cause a Change in Control.  “Non-Control Acquisition” shall mean an acquisition (A) by or under an employee benefit plan (or a trust forming a part thereof) maintained by (1) the Company or (2) any corporation, partnership or other person of which a majority of its voting power or its equity securities or equity interest is owned directly or indirectly by the Company or in which the Company serves as a general partner or manager (a “Subsidiary”), (B) by the Company or any Subsidiary, or (C) by any person in connection with a Non-Control Transaction (as hereinafter defined).  “Non-Control Transaction” shall mean a merger, consolidation, share exchange or reorganization involving the Company, in which (1) the stockholders of the Company, immediately before such merger, consolidation, share exchange or reorganization, own, directly or indirectly immediately following such merger, consolidation, share exchange or reorganization, at least 50% of the combined voting power of the outstanding voting securities of the corporation that is the successor in such merger, consolidation, share exchange or reorganization (the “Surviving Company”) in substantially the same proportion as their ownership of the Voting Securities immediately before such merger, consolidation, share exchange or reorganization, and (2) the individuals who were members of the Board of Directors of the Company immediately prior to the execution of the agreement providing for such merger, consolidation, share exchange or 

4

reorganization constitute at least 50% of the members of the board of directors of the Surviving Company;

(ii)    the individuals who constitute the Board as of the date hereof (the “Incumbent Board”) cease for any reason to constitute at least 50% of the Board; provided, however, that if the election, or nomination for election by the Company’s stockholders, of any new director was approved by a vote of at least two-thirds of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board; provided, further, that no individual shall be considered a member of the Incumbent Board if such individual initially assumed office as a result of either an actual or threatened “election contest” (as described in Rule 14a-11 promulgated under the Exchange Act) (an “Election Contest”) or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board of Directors (a “Proxy Contest”) including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest; or 

(iii)    the consummation of any of the following: (A) a merger, consolidation, share exchange or reorganization involving the Company (other than a Non-Control Transaction); (B) a complete liquidation or dissolution of the Company; or (C) the sale or other disposition of all or substantially all of the assets of the Company to any person (other than a transfer to a Subsidiary).

Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because any person (a “Subject Person”) acquired Beneficial Ownership of more than the permitted amount of the outstanding Voting Securities as a result of the acquisition of Voting Securities by the Company that, by reducing the number of Voting Securities outstanding, increases the proportional number of shares Beneficially Owned by such Subject Person, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of Voting Securities by the Company, and after such share acquisition by the Company, such Subject Person becomes the Beneficial Owner of any additional Voting Securities that increases the percentage of the then outstanding Voting Securities Beneficially Owned by such Subject Person, then a Change in Control shall occur.

(b)    “Cause” shall mean the termination of the Recipient’s employment because of the occurrence of any of the following events, as determined by the Board in accordance with the procedure below:

(i) the failure by the Recipient to attempt in good faith to perform his or her duties or to follow the lawful direction of the individual to whom the Recipient reports; provided, however, that the Company shall have provided the Recipient with written notice of such failure and the Recipient has been afforded at least fifteen (15) days to cure same;

(ii) the indictment of the Recipient for, or the Recipient’s conviction of or plea of guilty or nolo contendere to, a felony or any other serious crime involving moral turpitude or dishonesty;

5

(iii) the Recipient’s willfully engaging in misconduct in the performance of his or her duties (including theft, fraud, embezzlement, securities law violations, a material violation of the Company’s code of conduct or a material violation of other material written policies) that is injurious to the Company, monetarily or otherwise, in more than a de minimis manner;

(iv) the Recipient’s willfully engaging in misconduct unrelated to the performance of his or her duties for the Company that is materially injurious to the Company, monetarily or otherwise;

(v) the material breach by the Recipient of any material written agreement with the Company.

For purposes of this Section 4(b), no act, or failure to act, on the part of the Recipient shall be considered “willful” unless done, or omitted to be done, by the Recipient in bad faith and without reasonable belief that his or her action or omission was in the best interest of the Company.  Any termination shall be treated as a termination for Cause only if (i) the Recipient is given at least five (5) business days’ written notice of termination specifying the alleged Cause event and shall have the opportunity to appear (with counsel) before the full Board to present information regarding his or her views on the Cause event, and (ii) after such hearing, the Recipient is terminated for Cause by at least a majority of the Board.  After providing the notice of termination in the foregoing sentence, the Board may suspend the Recipient with full pay and benefits until a final determination pursuant to this Section 4(b) has been made.  Notwithstanding the foregoing provisions of this Section 4(b), if the Recipient is party to an employment agreement with the Company that provides a definition of Cause, such definition shall apply instead of the foregoing provisions of this Section 4(b).

(c)    “Good Reason” shall mean (i) a reduction in the Recipient’s base salary; (ii) a material diminution in the Recipient’s title or responsibilities; or (iii) relocation of the Recipient’s primary place of employment more than fifty miles; provided, however, that the Recipient may only terminate employment for Good Reason by delivering written notice to the Board within ninety (90) days following the date on which the Recipient first knows of the event constituting Good Reason, which notice specifically identifies the facts and circumstances claimed by the Recipient to constitute Good Reason, and the Company has failed to cure such facts and circumstances within thirty (30) days after receipt of such notice; and provided further, however, that if the Recipient is party to an employment agreement with the Company that provides a definition of Good Reason, such definition shall apply instead of the foregoing provisions of this Section 4(c).

5.    Tax Matters.  
    
(a)    83(b) Election.  The recipient may make an election to include in gross income in the year of transfer the fair market value of the Restricted LTIP Units granted hereunder in accordance with Section 83(b) of the Code.

(b)    Withholding and Taxes.  No later than the date as of which an amount first becomes includible in the gross income of the Recipient for income tax purposes or subject to the 

6

Federal Insurance Contributions Act withholding with respect to the Restricted LTIP Units granted hereunder, the Recipient will pay to the Company or, if appropriate, any of its subsidiaries, or make arrangements satisfactory to the Administrator regarding payment of, any United States federal, state or local or foreign taxes of any kind required by law to be withheld with respect to such amount.  The Company may cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from Restricted LTIP Units granted to the Recipient with an aggregate value that would satisfy the withholding amount due.  The obligations of the Company under this Agreement shall be conditional on such payment or arrangements, and the Company and its subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment otherwise due to the Recipient.  

BY SIGNING THIS AGREEMENT, THE RECIPIENT REPRESENTS THAT HE OR SHE HAS REVIEWED WITH HIS OR HER OWN TAX ADVISORS THE FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND THAT HE OR SHE IS RELYING SOLELY ON SUCH ADVISORS AND NOT ON ANY STATEMENTS OR REPRESENTATIONS OF THE COMPANY OR ANY OF ITS AGENTS.  THE RECIPIENT UNDERSTANDS AND AGREES THAT HE OR SHE (AND NOT THE COMPANY) SHALL BE RESPONSIBLE FOR ANY TAX LIABILITY THAT MAY ARISE AS A RESULT OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.

6.    Investment Representation; Registration.  The Recipient hereby warrants and represents to and agrees with the Company as follows:
(a)The LTIP Units issued pursuant to this Agreement will be acquired for the account of the Recipient for investment only and not with a view to, nor with any intention of, a distribution or resale thereof, in whole or in part, or the grant of any participation therein.  The Recipient acknowledges that the issuance of the LTIP Units has not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations thereunder, or the securities or real estate syndication laws of any state or other jurisdiction, and cannot be disposed of unless they are subsequently registered under the Securities Act and any applicable laws of states or other jurisdictions or an exemption from such registration is available.  The Recipient acknowledges that the Company does not have any intention of registering the resale of any LTIP Units issued hereunder under the Securities Act or of supplying the information necessary for the Recipient to sell any such LTIP Units; and that the Company and the Partnership shall be organized and operated so as to be exempt from registration under the Investment Company Act of 1940, as amended, and from the provisions of that statute designed to protect investors.
(b)    The Recipient also understands that the transfer of any LTIP Units issued pursuant to this Agreement will be subject to restrictions contained in the Partnership Agreement, as well as the restrictions set forth in this Agreement.
(c)    The Recipient acknowledges that (i) he or she has no obligation whatsoever to acquire the LTIP Units issued pursuant to this Agreement, (ii) his or her acquisition of the LTIP Units issued pursuant to this Agreement is not, and will not be, in any way whatsoever a condition of continued employment with the Company or any entity affiliated with the Company, (iii) neither 

7

the offer to the Recipient of the opportunity to acquire the LTIP Units or any shares of Stock issued pursuant to the Partnership Agreement nor this Agreement, shall be deemed to constitute a contract of employment or to impose any obligation upon the Company or any of its affiliates to continue to employ the Recipient, and (iv) nothing stated or implied in this Agreement or in the Partnership Agreement shall be construed to abrogate, amend or otherwise affect any rights or obligations with respect to employment which the Company or any of its affiliates or the Recipient may otherwise have by agreement or under law.
(d)    The Recipient acknowledges that he or she has been furnished a copy of the Partnership Agreement, has carefully read and understands the provisions of the Partnership Agreement, has had the opportunity to ask questions of the Company and has received answers from the Company concerning the provisions of the Partnership Agreement, and the terms and conditions of the offering of the LTIP Units.  The Recipient further acknowledges that he or she has been furnished information regarding the activities of the Company, has had the opportunity to ask questions of the Company concerning such activities, and is satisfied with all such information and such answers as he or she has received.  The Recipient acknowledges that no representation has been made by the Company otherwise by or on behalf of the Company as to any current value of the assets held by the Company or as to any prospective return on any LTIP Units issued pursuant to this Agreement.  The Recipient further acknowledges that he or she has not relied, in connection with the acquisition of the LTIP Units, upon any representations, warranties or agreements other than those set forth in this Agreement or the Partnership Agreement.  The Recipient further acknowledges that he or she provides services to the Company on a regular basis and that, in such capacity, the Recipient has access to all such information, and has such experience and involvement in connection with the business and operations of the Company, as the Recipient believes to be necessary and appropriate to make an informed decision to accept the LTIP Units granted pursuant to this Agreement.
(e)    The Recipient acknowledges that neither the Company nor any of its affiliates is rendering any tax, legal or financial advice or recommendation to acquire the LTIP Units issued pursuant to this Agreement.  The Recipient has been informed that he or she should consult his or her own tax, legal and financial advisors to the extent the Recipient seeks advice regarding these matters.
(f)    The Recipient makes the representation regarding his or her status as an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act as set forth below the Recipient’s name on the signature page hereto.
(g)    So long as the Recipient holds LTIP Units, the Recipient shall disclose to the Company in writing such information as may be reasonably requested with respect to direct or indirect ownership of any LTIP Units issued pursuant to this Agreement as the Company may deem reasonably necessary to ascertain and to establish compliance with provisions of the Code, applicable to the Company or to comply with requirements of any other appropriate taxing authority.
(h)    The Recipient shall indemnify and hold the Company harmless from and against any and all loss, cost, damage or liability due to or arising out of a breach of any representation, warranty or agreement of the Recipient in this Agreement or any other document 

8

furnished by it to the Company in connection with this Award, including, without limitation, the Partnership Agreement.
7.    Miscellaneous.
(a)    Entire Agreement.  This Agreement, the Plan and the Partnership Agreement contain the entire understanding and agreement of the Company and the Recipient concerning the subject matter hereof, and supersede all earlier negotiations and understandings, written or oral, between the parties with respect thereto.
(b)    Captions.  The captions and section numbers appearing in this Agreement are inserted only as a matter of convenience.  They do not define, limit, construe or describe the scope or intent of the provisions of this Agreement.
(c)    Counterparts.  This Agreement may be executed in counterparts, each of which when signed by the Company or the Recipient will be deemed an original and all of which together will be deemed the same agreement.
(d)    Notices.  Any notice or communication having to do with this Agreement must be given by personal delivery or by certified mail, return receipt requested, addressed, if to the Company or the Committee, to the attention of the General Counsel of the Company at the principal office of the Company and, if to the Recipient, to the Recipient’s last known address contained in the personnel records of the Company.
(e)    Succession and Transfer.  Each and all of the provisions of this Agreement are binding upon and inure to the benefit of the Company and the Recipient and their permitted successors, assigns and legal representatives.
(f)    Amendments.  Subject to the provisions of the Plan, this Agreement may be amended or modified at any time by an instrument in writing signed by the parties hereto.
(g)    Governing Law.  This Agreement and the rights of all persons claiming hereunder will be construed and determined in accordance with the laws of the State of Maryland without giving effect to the choice of law principles thereof.
(h)    Plan Controls.  This Agreement is made under and subject to the provisions of the Plan, and all of the provisions of the Plan are hereby incorporated by reference into this Agreement.  In the event of any conflict between the provisions of this Agreement and the provisions of the Plan, the provisions of the Plan shall govern.  By signing this Agreement, the Recipient confirms that he or she has received a copy of the Plan and has had an opportunity to review the contents thereof.
(i)    No Guarantee of Continued Service.  The Recipient acknowledges and agrees that nothing herein, including the opportunity to make an equity investment in the Company, shall be deemed to create any implication concerning the adequacy of the Recipient’s services to the Company, any Company Subsidiary or any Partnership or Partnership Subsidiary shall be construed 

9

as an agreement by the Company, any Company Subsidiary or any Partnership or Partnership Subsidiary, express or implied, to employ the Recipient or contract for the Recipient’s services, to restrict the right of the Company, any Company Subsidiary or any Partnership or Partnership Subsidiary, as applicable, to discharge the Recipient or cease contracting for the Recipient’s services or to modify, extend or otherwise affect in any manner whatsoever, the terms of any employment agreement or contract for services that may exist between the Recipient and the Company, any Company Subsidiary or any Partnership or Partnership Subsidiary, as applicable.

10

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

APARTMENT INVESTMENT AND
MANAGEMENT COMPANY

By:                            

		
	AIMCO PROPERTIES, L.P.
	 

By: AIMCO-GP, Inc., 
Its General Partner 

By:                            

RECIPIENT:

By:                            
    

Address:      

11

Section 6(f) Representation.  Please initial or check ALL of the boxes which correctly describe the Recipient.
		
	o
	The Recipient is a natural person:  (i) whose individual net worth (assets minus liabilities), or joint net worth with that person’s spouse, exceeds $1,000,000 ((a) excluding (1) as an asset, the value of such natural person’s primary residence and (2) as a liability, the outstanding indebtedness secured by such natural person’s primary residence up to the fair market value of such primary residence, provided, however, that if the amount of such outstanding indebtedness has increased within the previous 60 days, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability and (b) including, as a liability, the outstanding indebtedness secured by the natural person’s primary residence in excess of the fair market value of such primary residence), or (ii) who had an individual income in excess of $200,000 in each of the two most recent years or joint income with the person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year.

		
	o
	The Recipient is a natural person who is a director or executive officer (as defined below) of the Company.  As used herein, “executive officer” shall mean the president, any vice president in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company.

		
	o
	Neither of the prior boxes correctly describes the Recipient.

12

EXHIBIT A 

FORM OF LIMITED PARTNER SIGNATURE PAGE
The Participant, desiring to become one of the within named Limited Partners of AIMCO, L.P., hereby becomes a party to the Fourth Amended and Restated Agreement of Limited Partnership of AIMCO Properties, L.P., as amended through the date hereof (the “LP Agreement”).
The Participant constitutes and appoints the General Partner and its authorized officers and attorneys-in-fact, and each of those acting singly, in each case with full power of substitution, as the Participant’s true and lawful agent and attorney-in-fact, with full power and authority in the Participant’s name, place and stead to carry out all acts described in Section 2.4.A of the Partnership Agreement, such power of attorney to be irrevocable and a power coupled with an interest pursuant to Section 2.4.B of the LP Agreement.
The Participant agrees that this signature page may be attached to any counterpart of the Partnership Agreement.
	
	
	[PARTICIPANT]

	 

	 

	 

	By:                                                                   

	   Name:  

	   Date:

	 

	 

	Address of Limited Partner:

	 

	 

	 

	 

	 

	 

13

EXHIBIT B

This Exhibit sets forth the calculation methodology with respect to the Agreement.  Certain defined terms may be found at the end of this Exhibit B.  Terms not defined on this Exhibit B shall have the meaning set forth in the body of the Agreement.

Maximum LTIP Units:  [__________]

With respect to [     ]% of the Restricted LTIP Units:

	
			
	

Performance Level
	

Relative TSR vs. [________] TSR:
Performance vs. Index
Over Performance Period

	

Portion of Target Award Vesting
(“Vesting Portion”)

	

Threshold
	

 [___] bps

	[___]%

	Target
	

 [___] bps

	[___]%

	Maximum
	

 [___] bps

	[___]%

With respect to [     ]% of the Restricted LTIP Units:

	
			
	

Performance Level
	

Relative TSR vs. [________] TSR: 
Performance vs. Index
Over Performance Period

	

Portion of Target Award Vesting
(“Vesting Portion”)

	

Threshold
	

 [___] bps

	[___]%

	

Target
	

 [___] bps

	[___]%

	

Maximum
	

 [___] bps

	[___]%

TSR results above the Threshold level and below the Maximum level shall result in a Vesting Portion that is interpolated between the Threshold and Maximum Vesting Portions set forth on this Exhibit B.  TSR results 

14

below the Threshold level will cause the Restricted LTIP Units to be forfeited to the Company without payment of any consideration by the Company, and neither the Recipient nor any of his or her successors, heirs, assigns or personal representatives shall thereafter have any further rights or interests in such shares of Restricted LTIP Units.

If the performance level is above Target but as of the Determination Date the Company has negative absolute TSR with respect to the Performance Period, then the Restricted LTIP Units shall vest at the Target level as of the dates set forth in Section 2(b) of the Agreement, with the Vesting Portion in excess of Target (the “Excess Portion”) vesting only (a) with respect to [___]% of the Excess Portion, upon the Company’s achievement of positive absolute TSR with respect to the period beginning on the first day of the Performance Period; and (b) with respect to the remaining [___]% of the Excess Portion, on the later of (i) the Company’s achievement of positive absolute TSR with respect to the period beginning on the first day of the Performance Period and (ii) the Anniversary Date; provided, however, that if the Company has not achieved positive absolute TSR with respect to the period beginning on the first day of the Performance Period as of the third anniversary of the Determination Date, then the Excess Portion shall be forfeited to the Company without payment of any consideration by the Company, and neither the Recipient nor any of his or her successors, heirs, assigns or personal representatives shall thereafter have any further rights or interests in such shares of Restricted LTIP Units.

For purposes of these calculations:

“TSR” means the Company’s Total Shareholder Return as reported by SNL Financial or another third party judged by the Committee to be a reputable third party, which measurement shall be confirmed by the Committee.  For purposes of calculating Aimco’s TSR, the “starting” share price will be calculated using the average closing price for the 20-day trading period up to and including [_________] (i.e., the first trading day of the three-year performance period), and the “ending” share price be calculated using the average closing price for the 20-day period up to and including [__________].

When measuring the TSR of the Company, the calculation shall be adjusted as deemed appropriate by the Committee to reflect any change in corporate structure of the nature referenced in Section 3.4 of the Plan.

Measurement of the TSR of the [_______] Index and [_______] Index for purposes of comparison to the Company’s TSR shall be as reported by SNL Financial or another third party judged by the Committee to be a reputable third party, which measurement shall be confirmed by the Committee.

“bps” shall mean basis points, each of which shall equal 1/100th of 1%.

15EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

INTELLECTUAL PROPERTY LICENSE 

BY AND BETWEEN 

HOLOGIC, INC., 
 GEN-PROBE INCORPORATED 
 AND 

GRIFOLS DIAGNOSTIC SOLUTIONS INC. 

January 31, 2017 

  

					
		  		  	

 Table of Contents 

 

							
	 	 	 	  	Page	 
		
	 ARTICLE I DEFINITIONS
	  	 	1	  
			
	 Section 1.1
	 	 Certain Defined Terms
	  	 	1	  
	 Section 1.2
	 	 Table of Definitions
	  	 	5	  
		
	 ARTICLE II INTELLECTUAL PROPERTY LICENSE
	  	 	6	  
			
	 Section 2.1
	 	 License Grants to Licensee
	  	 	6	  
	 Section 2.2
	 	 License Grants to Licensor
	  	 	7	  
	 Section 2.3
	 	 Know-How and Copyright Transfer
	  	 	7	  
	 Section 2.4
	 	 Patent Laundering
	  	 	8	  
	 Section 2.5
	 	 Patent Marking
	  	 	8	  
	 Section 2.6
	 	 Secondary Patents
	  	 	8	  
	 Section 2.7
	 	 Applicable Agreement
	  	 	9	  
	 Section 2.8
	 	 Reservation of Patent Rights
	  	 	9	  
		
	 ARTICLE III TRADEMARK LICENSE
	  	 	9	  
			
	 Section 3.1
	 	 License Grant
	  	 	9	  
	 Section 3.2
	 	 Limitations on Scope of Trademark License
	  	 	9	  
	 Section 3.3
	 	 Transitional Use Only; Legal Requirements
	  	 	10	  
	 Section 3.4
	 	 Licensor’s Exercise of Quality Control
	  	 	10	  
	 Section 3.5
	 	 Goodwill
	  	 	10	  
	 Section 3.6
	 	 Reservation of Trademark Rights
	  	 	11	  
		
	 ARTICLE IV DURATION OF LICENSES AND TERMINATION
	  	 	11	  
			
	 Section 4.1
	 	 Agreement Term
	  	 	11	  
	 Section 4.2
	 	 Termination for Breach
	  	 	11	  
	 Section 4.3
	 	 Termination for Insolvency
	  	 	11	  
	 Section 4.4
	 	 Effect of Termination
	  	 	12	  
	 Section 4.5
	 	 Effect of Expiration
	  	 	12	  
	 Section 4.6
	 	 Sale of Licensed Intellectual Property
	  	 	12	  
	 Section 4.7
	 	 Survival
	  	 	12	  
	 Section 4.8
	 	 Acknowledgement
	  	 	12	  
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES
	  	 	13	  
			
	 Section 5.1
	 	 Mutual Representations and Warranties
	  	 	13	  
		
	 ARTICLE VI WARRANTY DISCLAIMER AND LIMITATION OF LIABILITY
	  	 	13	  
			
	 Section 6.1
	 	 WARRANTY DISCLAIMER
	  	 	13	  

  

					
		 	i	  	Intellectual Property Licence

							
	 ARTICLE VII MAINTENANCE AND ENFORCEMENT
	  	 	14	  
			
	 Section 7.1
	 	 Maintenance
	  	 	14	  
	 Section 7.2
	 	 Enforcement
	  	 	14	  
	 Section 7.3
	 	 Jointly Owned Intellectual Property
	  	 	15	  
	 Section 7.4
	 	 No Challenge
	  	 	15	  
		
	 ARTICLE VIII INDEMNIFICATION
	  	 	15	  
			
	 Section 8.1
	 	 Licensee Indemnification Obligations
	  	 	15	  
	 Section 8.2
	 	 Licensor Indemnification Obligations
	  	 	16	  
	 Section 8.3
	 	 Indemnification Procedures
	  	 	16	  
		
	 ARTICLE IX CONFIDENTIALITY
	  	 	17	  
			
	 Section 9.1
	 	 Confidential Information
	  	 	17	  
	 Section 9.2
	 	 Exceptions to Confidentiality Obligations
	  	 	17	  
	 Section 9.3
	 	 Required Disclosures
	  	 	18	  
	 Section 9.4
	 	 Publicity
	  	 	18	  
		
	 ARTICLE X MISCELLANEOUS
	  	 	18	  
			
	 Section 10.1
	 	 Section 365(n) of the Bankruptcy Code
	  	 	18	  
	 Section 10.2
	 	 Fees and Expenses
	  	 	18	  
	 Section 10.3
	 	 Amendment and Modification
	  	 	18	  
	 Section 10.4
	 	 Waiver
	  	 	18	  
	 Section 10.5
	 	 Notices
	  	 	19	  
	 Section 10.6
	 	 Interpretation
	  	 	20	  
	 Section 10.7
	 	 Entire Agreement
	  	 	20	  
	 Section 10.8
	 	 Third-Party Beneficiaries
	  	 	20	  
	 Section 10.9
	 	 Governing Law
	  	 	20	  
	 Section 10.10
	 	 Submission to Jurisdiction
	  	 	21	  
	 Section 10.11
	 	 Personal Liability
	  	 	21	  
	 Section 10.12
	 	 Assignment; Successors
	  	 	21	  
	 Section 10.13
	 	 Enforcement
	  	 	21	  
	 Section 10.14
	 	 Severability
	  	 	22	  
	 Section 10.15
	 	 Waiver of Jury Trial
	  	 	22	  
	 Section 10.16
	 	 Counterparts
	  	 	22	  
	 Section 10.17
	 	 Facsimile or .pdf Signature
	  	 	22	  
	 Section 10.18
	 	 No Presumption Against Drafting Party
	  	 	22	  

  

					
		 	ii	  	Intellectual Property Licence

 INTELLECTUAL PROPERTY LICENSE 

This INTELLECTUAL PROPERTY LICENSE (this “Agreement”), dated as of January 31, 2017 (the “Effective
Date”), is by and between, on the one hand, Hologic, Inc., a Delaware corporation (“Hologic”), and Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”, and, collectively with Hologic, “Licensor”) and, on the other hand, Grifols Diagnostic Solutions Inc., a Delaware corporation (“Licensee”). Licensor and
Licensee are referred to herein individually as a “Party” and collectively as the “Parties”. 
 RECITALS

 WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of December 14, 2016, by and between the Parties (the
“Purchase Agreement”), Licensor has agreed to sell, and Licensee has agreed to purchase, substantially all of the assets used in connection with, and liabilities relating to, nucleic acid probe-based testing in human blood, plasma
or other blood products or components, cells, organs, tissue, or cellular and tissue-based products intended for or associated with transfusion, implantation, infusion, transfer or transplantation; 

WHEREAS, Licensor is the owner of, or otherwise has the right to use and license, certain intellectual property used in the nucleic acid
probe-based testing of human blood, plasma, other blood products, human cells, organs or tissue intended for or associated with transfusion or transplantation; and 

WHEREAS, Licensor is willing to grant to Licensee the exclusive or co-exclusive right to exploit such
intellectual property as set forth in this Agreement, such use subject to the terms and conditions set forth herein. 
 AGREEMENT 

NOW THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, the receipt and sufficiency of
which are hereby acknowledged and agreed, and intending to be legally bound hereby, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS 

Section 1.1    Certain Defined Terms. For purposes of this Agreement, the following terms shall have the
meanings defined herein. To the extent a term is used but not defined herein, such term shall have the meaning ascribed to it in the Purchase Agreement: 

“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with, such first Person. For purposes of this definition, “control,” including the terms “controlled by” and “under common control
with,” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or executor, as general partner or
managing member, by contract or otherwise. 

  

					
		 	1	  	Intellectual Property Licence

 “Applicable Agreement” has the meaning set forth in the Confidential Disclosure
Letter. 
 “Applicable Agreement Counterparty” has the meaning set forth in the Confidential Disclosure Letter. 

“Business” has the meaning assigned in the Purchase Agreement. 

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law
to be closed in the City of New York or Barcelona, Spain. 
 “Collaboration Agreement” means that certain Collaboration
Agreement, dated as of January 31, 2017, by and between the Parties. 
 “Confidential Disclosure Letter” shall mean
that certain disclosure letter delivered by Licensor to Licensee in connection herewith. 
 “Confidential Information”
means all information of a confidential or proprietary nature disclosed by a Party to the other Party pursuant to this Agreement (including any information disclosed pursuant to any confidentiality or nondisclosure agreement entered into between the
Parties) that the disclosing Party designates as confidential or proprietary to the receiving Party or which, under the circumstances surrounding such disclosure, the receiving Party should recognize should be treated as confidential or proprietary.

 “Controlled” means, with respect to any Intellectual Property, possession of the right, whether directly or indirectly,
and whether by ownership, license, or otherwise, to convey ownership of, grant a license, sublicense or covenant-not-to-sue, as
applicable, under such Intellectual Property, as provided herein, without violating the terms of any Contract or other arrangement with any Third Party. 

“Copyrights” means original works of authorship in any medium of expression, whether or not published, all copyrights therein
(whether registered, applied-for or unregistered), all registrations and applications therefor and all extensions and renewals thereof, throughout the world. 

“Exploit” means, with respect to the Licensed Patents, Licensor Improvements and Licensed
Know-How, to make, have made, import, use, sell, offer for sale or otherwise dispose of and, with respect to the Licensed Copyrights, and Licensor Improvements, to reproduce, distribute, modify and prepare
derivative works of. “Exploitation” means the act of Exploiting a product, process or service. 
 “Governmental
Authority” means any United States or non-United States federal, state, local or other governmental or quasi-governmental, regulatory, self-regulatory or administrative authority, agency or commission
or any judicial or arbitral body. 
 “Intellectual Property” has the meaning assigned to it in the Purchase Agreement. 

  

					
		 	2	  	Intellectual Property Licence

 “Jointly Owned Intellectual Property” has the meaning set forth in the
Collaboration Agreement. 
 “Know-How” means technical information, know-how and trade secrets, including biological, chemical, pharmacological, toxicological, clinical and assay, manufacturing data, preclinical and clinical data, the specifications of ingredients, the manufacturing
processes, formulation, specifications, sourcing information, quality control and testing procedures. 
 “Law” means any
statute, law, ordinance, treaty, regulation, rule, code, injunction, judgment, decree, order, or applicable other requirement or rule of law issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of
any Governmental Authority. 
 “Liabilities” means any indebtedness, obligation, liability, claim, suit, judgment, demand,
loss, damage, deficiency, cost, expense, fee, fine, penalty, responsibility or obligation of any kind or nature, whether known or unknown, express or implied, primary or secondary, direct or indirect, absolute, accrued, contingent or otherwise and
whether due or to become due. 
 “Licensed Copyrights” means (i) all Copyrights and Software that are (a) owned
or otherwise Controlled by Licensor or any of its Affiliates as of the Effective Date and (b) related to the NAT Business, as currently conducted, excluding commercially available
off-the-shelf Software, (ii) Licensor’s interest in all Copyrights and Software in and to the Jointly Owned Intellectual Property, and (iii) any
Copyrights in and to any Hologic Owned Intellectual Property included in the Licensed Intellectual Property pursuant to Section 6.4 of the Collaboration Agreement. 

“Licensed Donor Screening Field” means the field of nucleic acid probe-based testing in human blood, plasma, other blood
products or components, cells or other biological material intended for direct transfusion or other administration to humans, or for further manufacture. 

“Licensed Fields” means the Licensed Donor Screening Field and the Licensed Transplantation Field, collectively. 

“Licensed Intellectual Property” means, collectively, the Licensed Copyrights, Licensed
Know-How, Licensed Patents, Licensed Marks and Licensor Improvements, provided, however, that Selected IP shall be included in Licensed Intellectual Property solely to the extent and for such
time period that such Selected IP is Controlled by Licensor during the Term of this Agreement. 
 “Licensed Know-How” means (i) all Know-How that is (a) owned or otherwise Controlled by Licensor or any of its Affiliates as of the Effective Date and
(b) related to the NAT Business, as currently conducted, (ii) Licensor’s interest in all Know-How in and to the Jointly Owned Intellectual Property, and (iii) any Know-How in and to any Hologic Owned Intellectual Property included in the Licensed Intellectual Property pursuant to Section 6.4 of the Collaboration Agreement. 

  

					
		 	3	  	Intellectual Property Licence

 “Licensed Marks” means the trademarks set forth in Section 3 of the
Confidential Disclosure Letter. 
 “Licensed Patents” means (i) all Patents that are (a) owned or otherwise
Controlled by Licensor or any of its Affiliates as of the Effective Date and (b) related to the NAT Business, as currently conducted, (ii) Licensor’s interest in all Patents in and to the Jointly Owned Intellectual Property, and
(iii) any Patents in and to any Hologic Owned Intellectual Property included in the Licensed Intellectual Property pursuant to Section 6.4 of the Collaboration Agreement. As of the Effective Date, the Licensed Patents include the Patents
set forth in Section 2 of the Confidential Disclosure Letter and Section 5 of the Confidential Disclosure Letter. 

“Licensed Products” means products, processes or services used in connection with the Licensed Fields. 

“Licensed Transplantation Field” means nucleic acid probe-based testing of biological materials intended for transplantation
of human cells, organs or tissues. 
 “Molecular Detection Field” means nucleic acid probe-based testing for the detection,
identification, quantification and/or monitoring of infectious agents or genetic material in humans, excluding the Licensed Donor Screening Field and the Licensed Transplantation Field. 

“NAT Business” means nucleic acid probe-based testing in human specimens, excluding oncology testing and compositions and
methods for immobilizing circulating tumor cells. 
 “Patents” means (a) patents and patent applications (provisional
and non-provisional) anywhere in the world, (b) all divisionals, continuations, continuations in-part thereof, or any other patent application claiming priority, or
entitled to claim priority, directly or indirectly to (i) any such patents or patent applications or (ii) any patent or patent application from which such patents or patent applications claim, or is entitled to claim, direct or indirect
priority, and (c) all patents issuing on any of the foregoing anywhere in the world, together with all registrations, reissues, re-examinations, patents of addition, renewals, supplemental protection
certificates, or extensions of any of the foregoing anywhere in the world. 
 “Person” means an individual, corporation,
partnership, limited liability company, limited liability partnership, syndicate, person, trust, association, organization or other entity, including any Governmental Authority, and including any successor, by merger or otherwise, of any of the
foregoing. 
 “Prosecution and Maintenance” means, with regard to any Patents, the preparation, filing, prosecution and
maintenance of such Patents, as well as re-examinations and reissues with respect to such Patents, together with the conduct of interferences, the defense of oppositions and other similar proceedings before
national or supranational patent offices with respect to such Patents. For avoidance of doubt, Prosecution and Maintenance shall exclude the enforcement or defense of Patents in any U.S. federal court, international trade commission panel or foreign
counterpart thereof. “Prosecute and Maintain” have the correlative meanings. 

  

					
		 	4	  	Intellectual Property Licence

 “Secondary Patents” means the Patents set forth in Section 5 of the
Confidential Disclosure Letter. 
 “Selected IP” has the meaning set forth in the Confidential Disclosure Letter. 

“Selected IP Licensor” has the meaning set forth in the Confidential Disclosure Letter. 

“Software” means computer software and algorithms, the copyrights therein and thereto, and the object code and source code
thereto, including a description of the procedure for generating the object code of a level sufficient to enable a programmer reasonably fluent in the programming language to build, operate, support and maintain, develop modifications, upgrades,
updates, adaptations, enhancements, new versions and other derivative works and improvements of, and develop computer programs compatible with, such source code. 

“Third Party” means any Person other than Licensor, Licensee, and their respective Affiliates. 

Section 1.2    Table of Definitions. The following terms have the meanings set forth in the Sections
referenced below: 
  

					
	 Definition
	  	Location	 
	Agreement	  	 	Preamble	  
	Assigned IP	  	 	7.1(b)	  
	Bankruptcy Code	  	 	10.1	  
	Copyright Term	  	 	4.1	  
	Effective Date	  	 	Preamble	  
	Gen-Probe	  	 	Preamble	  
	Hologic	  	 	Preamble	  
	Indemnified Party	  	 	8.3(a)	  
	Indemnifying Party	  	 	8.3(a)	  
	Know-How Term	  	 	4.1	  
	Licensee	  	 	Preamble	  
	Licensee Improvements	  	 	2.1(d)	  
	Licensee Indemnified Party	  	 	8.2	  
	Licensor	  	 	Preamble	  
	Licensor Improvements	  	 	2.1(d)	  
	Licensor Indemnified Party	  	 	8.1	  
	Party/Parties	  	 	Preamble	  
	Patent Term	  	 	4.1	  
	Purchase Agreement	  	 	Recitals	  
	Term	  	 	4.1	  
	Third Party Claim	  	 	8.3(a)	  
	Third Party Infringement	  	 	7.2(a)	  
	Trademark Term	  	 	4.1	  

  

					
		 	5	  	Intellectual Property Licence

 ARTICLE II 

INTELLECTUAL PROPERTY LICENSE 

Section 2.1    License Grants to Licensee. 

(a)    Licensed Donor Screening Field. Subject to the terms and conditions set forth in this Agreement, Licensor
hereby grants, and shall cause its applicable Affiliates (including Gen-Probe) to grant, to Licensee, and Licensee hereby accepts, an irrevocable (except as set forth in Article IV), exclusive, worldwide,
perpetual (except as set forth in Article IV), fully paid-up, royalty-free, non-sublicenseable (except as set forth in Section 2.1(c)), non-transferable (except as set forth in Section 10.12) license under the Licensed Patents, Licensed Know-How, Licensed Copyrights and Licensor Improvements to Exploit
the Licensed Products in the Licensed Donor Screening Field. Notwithstanding the foregoing, with respect to Hologic Owned Intellectual Property included in the Licensed Intellectual Property pursuant to Section 6.4 of the Collaboration
Agreement, the license under this Section 2.1(a) shall be subject to any payment terms which may be agreed by the Parties. 

(b)    Licensed Transplantation Field. Subject to the terms and conditions set forth in this Agreement, Licensor
hereby grants, and shall cause its applicable Affiliates (including Gen-Probe) to grant, to Licensee, and Licensee hereby accepts, a sole, irrevocable (except as set forth in Article IV), worldwide,
perpetual (except as set forth in Article IV), fully paid-up, royalty-free, non-sublicenseable (except as set forth in Section 2.1(c)), non-transferable (except as set forth in Section 10.12) license under the Licensed Patents, Licensed Know-How, Licensed Copyrights and Licensor Improvements to Exploit
the Licensed Products in the Licensed Transplantation Field. For purposes of this Section 2.1(b), “sole” shall mean that Licensor shall not grant a license to any Third Party, or permit any Third Party to operate, under the Licensed
Patents, Licensed Know-How, Licensed Copyrights or Licensor Improvements to Exploit the Licensed Products in the Licensed Transplantation Field, but retains a
co-exclusive right, with Licensee; provided that Licensor may sublicense the Licensed Patents, Licensed Know-How, Licensed Copyrights or Licensor Improvements to
(i) Affiliates of Licensor to Exploit the Licensed Products in the Licensed Transplantation Field, (ii) Third Parties in the Licensed Transplantation Field to provide products or services to Licensor solely to the extent necessary for such
products or services to be provided to Licensor by such Third Parties (e.g., Third Party consultants, manufacturers and distributors) and (iii) end users of the Licensed Products in the Licensed Transplantation Field. Notwithstanding the
foregoing, with respect to Hologic Owned Intellectual Property included in the Licensed Intellectual Property pursuant to Section 6.4 of the Collaboration Agreement, the license under this Section 2.1(b) shall be subject to the payment terms
agreed by the Parties. 
 (c)    Sublicensing Rights. Licensee may sublicense the rights granted to Licensee
pursuant to Section 2.1(a), Section 2.1(b) and Section 3.1 to (i) Affiliates of Licensee, (ii) Third Parties providing products or services to Licensee solely to the extent necessary for such products or services to be
provided to Licensee by such Third Parties (e.g., Third Party consultants, manufacturers and distributors) and (iii) end users of the Licensed Products in the Licensed Fields; provided that, in each case, the applicable sublicensee is bound by
confidentiality obligations substantially similar to those set forth in Article IX. 

  

					
		 	6	  	Intellectual Property Licence

 (d)    Improvements. Licensee acknowledges that Licensor owns and will
continue to own the Licensed Patents and all rights therein. Title and ownership rights, including all intellectual property rights, throughout the world in any improvement, enhancement or modification to the Licensed Patents, Licensed Know-How or Licensed Copyrights made, conceived or reduced to practice by or on behalf of (a) Licensor or its Affiliates shall vest in Licensor (the “Licensor Improvements”) and
(b) Licensee or its Affiliates shall vest in Licensee (the “Licensee Improvements”). 

(e)    Reservation of Rights. Licensee agrees and acknowledges that it shall have no rights hereunder under the
Licensed Intellectual Property outside of the Licensed Fields, including in the Molecular Detection Field. 

Section 2.2    License Grants to Licensor. 

(a)    Licensee Improvements. Licensee hereby grants to Licensor, and Licensor hereby accepts, an irrevocable, non-exclusive, worldwide, perpetual, fully paid-up, royalty-free, non-sublicenseable (except as set forth in Section 2.2(c)), non-transferable (except as set forth in Section 10.12) license under the Licensee Improvements to Exploit products, processes and services in the Molecular Detection Field and the Licensed Transplantation
Field. 
 (b)    Assigned IP. Licensee hereby grants to Licensor, and Licensor hereby accepts, an irrevocable, non-exclusive, worldwide, perpetual, fully paid-up, royalty-free, non-sublicenseable (except as set forth in Section 2.2(c)), non-transferable (except as set forth in Section 10.12) license under Licensee’s interest in all Patents, Copyrights and Know-How in and to the Assigned IP, in each
case to Exploit products, processes and services in the Molecular Detection Field and the Licensed Transplantation Field. 

(c)    Sublicensing Rights. Licensor may sublicense the rights granted to Licensor pursuant to Section 2.2(a)
and Section 2.2(b) to (i) Affiliates of Licensor, (ii) Third Parties providing products or services to Licensor solely to the extent necessary for such products or services to be provided by such Third Parties (e.g., Third Party
consultants, manufacturers and distributors) and (iii) end users of the products and services in the Molecular Detection Field and the Licensed Transplantation Field; provided that, in each case, the applicable sublicensee is bound by
confidentiality obligations substantially similar to those set forth in Article IX. 
 (d)    Reservation of
Rights. Licensor agrees and acknowledges that it shall have no rights hereunder under any of the Licensed Intellectual Property, Licensee Improvements, Jointly Owned Intellectual Property or Assigned IP in the Licensed Donor Screening Field.

 Section 2.3    Know-How and Copyright Transfer. During the ninety
(90) day period following the completion, transfer or provision to Licensee (as applicable) of the applicable technology or assets pursuant to the Purchase Agreement or this Agreement, at Licensor’s reasonable cost and expense, Licensor
shall provide to Licensee copies of all Licensed Know-How then in existence, all Licensed Copyrights (other than the Selected IP), as set forth in Section 6 of the Confidential Disclosure Letter, and
additional Licensed Copyrights requested by 

  

					
		 	7	  	Intellectual Property Licence

 
Licensee during the Term, and shall provide reasonable consultation, training and knowledge transfer to Licensee, in order to enable Licensee to exercise all of its rights under this Agreement.
In addition, as soon as reasonably practicable following written request of Licensee during the Term (and no more frequently than once each calendar quarter), Licensor shall transfer to Licensee any Licensor Improvements that have been developed and
have not been previously transferred to Licensee, and shall comply with the provisions of this Section 2.3 with respect to all Know-How and Copyrights in and to such Licensor Improvements. Simultaneously
with the provision of any Know-How and Copyrights under this Section 2.3, Licensor shall provide to Licensee copies of all user manuals, operating manuals, technical manuals and any other instructions,
specifications, documents or materials, in any form or media, that describe the functionality, installation, testing, operation, use, maintenance, support, or technical or other components, features or requirements, of the applicable Know-How and Copyrights. Licensee may make available the object code and source code with respect to Software in and to Licensed Copyrights transferred to Licensee under this Section 2.3 to any employees,
contractors or agents of Licensee or its Affiliates; provided that: (a) all such employees, contractors and agents are bound by confidentiality obligations substantially similar to those set forth in Article IX with respect to such object code
and source code; (b) no more than six such employees, contractors or agents have access to such object code and source code at any given time; (c) Licensee performs a criminal background check on each such employee, contractor or agent
prior to making available such object code or source code to such employee, contractor and agent; and (d) Licensee does not make available such object code or source code to any such employee, contractor or agent who has been convicted of, pled
guilty or nolo contendere to, a crime involving breach of trust or dishonesty or who refuses to provide consent with respect to Licensee’s performance of such background check. The Parties acknowledge and agree that any Selected IP that
constitutes Licensed Intellectual Property shall not be transferred pursuant to this Section 2.3 and instead shall be the subject of separate arrangements between the Parties and the Selected IP Licensor. 

Section 2.4    Patent Laundering. Licensee agrees that the licenses granted hereunder are not intended to
cover contract activities that Licensee may undertake on behalf of Third Parties. As a result, Licensed Products shall exclude any products produced or provided by Licensee for the benefit of a Third Party (a) from designs or instructions
received in a substantially completed form from that Third Party, (b) for resale to that Third Party (or to customers of, or as directed by, that Third Party) on essentially an exclusive basis, and (c) not otherwise branded with a Licensee
trademark. 
 Section 2.5    Patent Marking. Licensee shall comply with all applicable Laws relating to the
proper use of legends and proprietary notices and designation of the Licensed Patents. 

Section 2.6    Secondary Patents. Licensor may sell, transfer, or assign to a Third Party one or more of
the Secondary Patents without the consent of Licensee, and upon such sale, transfer or assignment and Licensee’s receipt of written notice of such sale, transfer or assignment, such Secondary Patent(s) shall be deemed removed from
Section 5 of the Confidential Disclosure Letter and shall no longer be “Licensed Patents” subject to the licenses granted hereunder. The Secondary Patents shall not be subject to any of the terms and conditions of this Agreement other
than as set forth in this Article II. 

  

					
		 	8	  	Intellectual Property Licence

 Section 2.7    Applicable Agreement. The Parties acknowledge and
agree that (a) Gen-Probe is a party to the Applicable Agreement, which grants certain rights and imposes certain conditions with respect to certain transcription-based amplification patent rights; and
(b) Licensee is a “Licensee” under the Applicable Agreement, entitled to the applicable rights and benefits, and subject to the applicable restrictions, therein. Licensee agrees, at the request of the Applicable Agreement
Counterparty, to permit and to cooperate fully with an annual review of its manufacturing records (and such other records as may be required) by an impartial, technically qualified Third Party to verify compliance with the provisions of
Section 3.3 of the Applicable Agreement. Selection of such Third Party shall be subject to the approval of Licensee, such approval not to be unreasonably withheld, delayed or conditioned. The results of such a review as provided to the
Applicable Agreement Counterparty will consist solely of a finding of compliance or noncompliance. The cost of such review shall be borne by the Applicable Agreement Counterparty and shall not be unreasonably burdensome for Licensee. Gen-Probe represents and warrants, as of the Effective Date, that it is not in breach of the Applicable Agreement, and the Applicable Agreement is in full force and effect. Upon notice by the Applicable
Agreement Counterparty that Gen-Probe is in breach of the Applicable Agreement, (i) Licensor shall promptly (and, in any event, before the effective date of termination of the Applicable Agreement)
provide express written notice to the Applicable Agreement Counterparty of Licensee’s status as a “Licensee” under the Applicable Agreement, and (ii) Licensee agrees to be bound by the applicable terms and conditions of the
Applicable Agreement. 
 Section 2.8    Reservation of Patent Rights. Except for the rights expressly
granted to Licensee under this Agreement with respect to the Licensed Patents, no license, right, title or interest in, to or under any Licensed Patent is granted to Licensee, either expressly or by implication, estoppel or otherwise. Any and all
rights not expressly granted to a Party in this Agreement are reserved by the other Party. 
 ARTICLE III 

TRADEMARK LICENSE 

Section 3.1    License Grant. Subject to the terms and conditions set forth in this Agreement, Licensor
hereby grants, and shall cause its applicable Affiliates (including Gen-Probe) to grant, to Licensee, and Licensee hereby accepts, a non-exclusive, worldwide, fully paid-up, royalty-free, non-sublicenseable (except as set forth in Section 2.1(c)), non-transferable (except as set forth in
Section 10.12) license to use the Licensed Marks in connection with the Exploitation of Licensed Products in the Licensed Fields during the Trademark Term. 

Section 3.2    Limitations on Scope of Trademark License. The Licensed Marks must be used
substantially in the same manner, including in the same style, typeface and graphic appearance, and to the same extent as the same was used by Licensor immediately prior to the Effective Date. Licensee is not granted a license hereunder to use any
domain names or social media addresses. Licensee is solely permitted to use the Licensed Marks in the Licensed Fields and in a manner that is in conformity with Licensor’s generally applicable guidelines regarding quality control (as set forth
in Section 4 of the Confidential Disclosure Letter, which may be updated from time to time by Licensor) and the quality control provisions set forth in Section 3.4. 

  

					
		 	9	  	Intellectual Property Licence

 Section 3.3    Transitional Use Only; Legal Requirements.
Licensee acknowledges and agrees that the purpose of the license granted in Section 3.1 is solely to provide Licensee with a reasonable transition period during which it can wind-down its use of the Licensed Marks. Licensee shall use
commercially reasonable efforts to cease and discontinue use of the Licensed Marks as soon as reasonably practicable after the Effective Date and shall in no event use the Licensed Marks after the end of the Trademark Term; provided that after the
Trademark Term, Licensee may use the Licensed Marks and Licensor’s corporate name solely as necessary to comply with applicable Law (e.g., if required to identify Licensor as the manufacturer of a Licensed Product). Upon the expiration or
earlier termination of this Agreement, Licensee shall not knowingly use any Licensed Marks or any trademark that is confusingly similar to or dilutive of the Licensed Marks, or any variation, derivation or colorable imitation thereof. 

Section 3.4    Licensor’s Exercise of Quality Control. 

(a)    Licensee acknowledges the importance of Licensor’s exercise of quality control over the use of the Licensed
Marks in order to preserve the continued integrity and validity of the Licensed Marks and to protect the value and goodwill associated with the Licensed Marks, and that, as between the Parties, Licensor has the sole right to exercise such control.

 (b)    At least once every six (6) calendar months, after written request from Licensor, Licensee shall deliver
to Licensor (or its designated Affiliate) representative samples of the manner in which Licensee used the Licensed Marks during the preceding six (6) month period. Licensor shall also have the right to periodically inspect and evaluate the
manner in which Licensee uses the Licensed Marks, including the rights to (i) periodically evaluate the quality of the Licensed Products offered by Licensee using the Licensed Marks and (ii) periodically request samples of materials on
which Licensee uses the Licensed Marks. Such evaluations shall be meant to ensure that Licensee is using the Licensed Marks in a manner designed to maintain or enhance the reputation and integrity of the Licensed Marks and the goodwill associated
therewith, and Licensor reserves all rights of approval which are necessary to achieve this result. 
 (c)    If
Licensee’s use of the Licensed Marks does not comply with the applicable quality or usage standards of this Agreement, upon Licensee’s receipt of written notice thereof, Licensee shall take all necessary steps to remedy any such non-compliance or to cease such non-complying use. Licensee acknowledges and agrees that the material and repeated uncured failure to adhere to the quality or usage standards
set forth in this Agreement shall entitle Licensor to terminate the license to the Licensed Marks set forth in Section 3.1. 

Section 3.5    Goodwill. All goodwill and improved reputation in respect of, associated with, or generated by
Licensee’s use of the Licensed Marks under this Agreement shall inure to the sole benefit of Licensor. Licensee shall include trademark and other notices in connection with the use of the Licensed Marks as reasonably required by Licensor from
time to time. Licensee acknowledges that, upon any expiration or termination of this Agreement, no monetary value shall be attributable to any goodwill associated with the use of the Licensed Marks by Licensee. 

  

					
		 	10	  	Intellectual Property Licence

 Section 3.6    Reservation of Trademark Rights. Except for the
rights expressly granted to Licensee under this Agreement with respect to the Licensed Marks, no license, right, title or interest in, to or under any Licensed Marks is granted to Licensee, either expressly or by implication, estoppel or otherwise.
Licensor hereby reserves the right to use and grant others the right to use the Licensed Marks alone or in association with any other trademark, service mark or name, as trademarks, trade names and/or service marks for any purpose whatsoever in any
jurisdiction. Any and all rights not expressly granted to Licensee in this Agreement are reserved by Licensor. 
 ARTICLE IV 

DURATION OF LICENSES AND TERMINATION 

Section 4.1    Agreement Term. This Agreement and the licenses granted herein shall be effective as of
the Effective Date and shall remain in effect perpetually, other than (a) with respect to the Licensed Marks, subject to Section 3.3, the rights granted hereunder shall endure until the second anniversary of the Effective Date (the
“Trademark Term”), (b) with respect to the Licensed Patents, the rights granted hereunder shall endure until the expiration of the last to expire claim in such Licensed Patents and, in the event there becomes a time when no issued
Patents remain, such time when the last claim in an applied-for Patent has been pending for ten years (the “Patent Term”), (c) with respect to the Licensed Copyrights, the rights granted
hereunder shall endure until the expiration of the last to expire of the Licensed Copyrights (the “Copyright Term”) and (d) with respect to the Licensed Know-How, Licensor Improvements
and Licensee Improvements, the rights granted hereunder shall endure for so long as any rights in such Licensed Know-How, Licensor Improvements and Licensee Improvements remain in effect (the “Know-How Term”, and together with the Trademark Term, Patent Term and Copyright Term, the “Term”). 

Section 4.2    Termination for Breach. In the event that Licensee knowingly and intentionally Exploits the
Licensed Patents, Licensed Know-How, Licensed Copyrights or Licensor Improvements in the Molecular Detection Field, Licensor shall have the right to immediately terminate this Agreement upon written notice to
Licensee if (a) Licensor has given written notice to Licensee specifying such breach, (b) such breach remains uncured for one-hundred twenty (120) days or more following the date of such notice
(provided that such breach shall be deemed cured if Licensee has undertaken prompt, good faith actions to mitigate any negative consequences of such breach and has terminated such Exploitation on a going-forward basis), and (c) upon the order
or judgment of a court of competent jurisdiction holding that Licensee did so knowingly and intentionally Exploit the Licensed Patents, Licensed Know-How, Licensed Copyrights or Licensor Improvements in the
Molecular Detection Field. In the event this Agreement has been terminated pursuant to this Section 4.2 and Licensee continues to Exploit the Licensed Patents, Licensed Know-How, Licensed Copyrights or
Licensor Improvements in the Molecular Detection Field, Licensor shall be entitled to seek an injunction to enjoin Licensee from such continued Exploitation. The remedies set forth in this Section 4.2 are Licensor’s sole remedy for the
actions set forth in the first sentence of this Section 4.2. 
 Section 4.3    Termination for
Insolvency. Licensor shall have the right to immediately terminate this Agreement, or any or all licenses granted herein, upon written notice to Licensee (a) in the event of a liquidation, dissolution or
winding-up, or (b) upon the appointment of a 

  

					
		 	11	  	Intellectual Property Licence

 
receiver for Licensee or upon the filing by Licensee of a petition under the Federal Bankruptcy Act or sixty (60) days after the filing of an involuntary bankruptcy petition where such
petition has not been vacated. 
 Section 4.4    Effect of Termination. Upon the termination of this
Agreement or the termination of a license granted hereunder, in each case pursuant to Section 4.2 or Section 4.3, the applicable license granted in this Agreement shall terminate and Licensee shall have no further right to use such
Licensed Intellectual Property (other than Jointly Owned Intellectual Property) and shall cease using any inventions or refrain from making, using, selling, offering for sale and importing any product covered by such Licensed Intellectual Property
(other than Jointly Owned Intellectual Property). 
 Section 4.5    Effect of Expiration. 

(a)    Upon the expiration of the Trademark Term, the license granted in this Agreement to the Licensed Marks shall
terminate and Licensee shall have no further right to use the Licensed Marks. 
 (b)    Upon the expiration of each
Licensed Patent or claim therein, Licensee shall have the unrestricted right to Exploit products, processes and services under such Licensed Patent as permitted by Law. 

(c)    Upon the expiration of each Licensed Copyright, Licensee shall have the unrestricted right to Exploit products,
processes and services under the Licensed Copyright as permitted by Law. 
 Section 4.6    Sale of Licensed
Intellectual Property. Should Licensor sell any of the Licensed Intellectual Property to a Third Party, Licensor shall ensure that the acquiror of such Licensed Intellectual Property shall execute a written agreement under which such acquiror
agrees to be bound by all obligations of Licensor under this Agreement. Licensor shall use commercially reasonable efforts to inform Licensee of any proposed transaction involving a sale, transfer, license or other alienation of any of the Licensed
Intellectual Property at least thirty (30) days in advance of any such contemplated transaction and following the closing of such transaction, promptly provide a copy of such written agreement to Licensee. 

Section 4.7    Survival. Section 2.8, Section 3.5, Section 3.6, this Section 4.7 and
Article I, Article VI, Article VIII, Article IX and Article X shall survive any termination or expiration of this Agreement. Article VII shall survive any termination or expiration of this Agreement solely with respect to
Jointly Owned Intellectual Property until the expiration of the last to expire claim in such Jointly Owned Intellectual Property. 

Section 4.8    Acknowledgement. The Parties acknowledge and agree that nothing in this Article IV shall limit
or restrict either Party’s remedies for any breaches of this Agreement not expressly addressed in this Article IV. 

  

					
		 	12	  	Intellectual Property Licence

 ARTICLE V 

REPRESENTATIONS AND WARRANTIES 

Section 5.1    Mutual Representations and Warranties. Each Party represents and warrants to the other Party,
that: 
 (a)    such Party is duly organized, validly existing and in good standing (or to the extent such concept is
not applicable in the relevant jurisdiction, is up to date in filing its corporate returns) under the applicable Laws of the jurisdiction of its organization and has full power and authority to enter into this Agreement and to carry out the
provisions hereof; 
 (b)    execution of this Agreement and the performance by such Party of its obligations hereunder
have been duly authorized; 
 (c)    this Agreement has been duly executed and delivered on behalf of such Party and
constitutes a legal, valid, binding obligation enforceable against it in accordance with the terms hereof; 
 (d)    the
performance of this Agreement by such Party does not create a breach or default under any other agreement to which it is a party, which breach or default would adversely affect such Party’s performance, or the other Party’s rights or
performance, under this Agreement; 
 (e)    the execution, delivery and performance of this Agreement by such Party
does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any applicable Laws of any court, governmental body or administrative or other agency having jurisdiction
over such Party; and 
 (f)    no government authorization, consent, approval, license, exemption of or filing or
registration with any court or governmental authority, under any applicable Laws in effect as of the Effective Date, is necessary in connection with the execution and delivery of this Agreement, or for the performance by such Party of its
obligations under this Agreement, except as may be required under the Purchase Agreement or for any such consent or approval obtained prior to the Effective Date. 

ARTICLE VI 
 WARRANTY
DISCLAIMER AND LIMITATION OF LIABILITY 
 Section 6.1    WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT OR THE PURCHASE AGREEMENT, (A) THE RIGHTS AND LICENSES GRANTED HEREUNDER ARE PROVIDED “AS IS”, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED (INCLUDING
ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, REGISTRABILITY, TITLE OR NON-INFRINGEMENT AND IMPLIED WARRANTIES ARISING FROM COURSE OF DEALING OR COURSE OF PERFORMANCE),
AND (B) NEITHER PARTY ASSUMES ANY RESPONSIBILITY OF ANY KIND WHATSOEVER WITH RESPECT TO THE OTHER PARTY’S USE OF INTELLECTUAL PROPERTY LICENSED HEREUNDER. 

  

					
		 	13	  	Intellectual Property Licence

 ARTICLE VII 

MAINTENANCE AND ENFORCEMENT 

Section 7.1    Maintenance. 

(a)    Licensor shall use commercially reasonable efforts to Prosecute and Maintain, at its sole cost and expense, any
rights in and to the Licensed Intellectual Property. Promptly after the Effective Date, the Parties will work together in good faith to agree upon an information sharing methodology and process with respect to the Licensed Intellectual Property,
and, upon Licensee’s request, Licensor shall (i) use commercially reasonable efforts to keep Licensee informed respect to the Prosecution and Maintenance of the Licensed Intellectual Property, (ii) provide copies of all substantive
office actions or any other substantive documents that Licensor receives from any patent office in connection with the Prosecution and Maintenance of the Licensed Intellectual Property, (iii) provide notices of all interferences, reissues, re-examinations, oppositions or requests for patent term extensions in connection with the Prosecution and Maintenance of the Licensed Intellectual Property, (iv) provide Licensee with a reasonable opportunity
to comment on material developments with respect to the Prosecution and Maintenance of the Licensed Intellectual Property and (v) in good faith consider any comments made by and actions recommended by Licensee in connection with the Prosecution
and Maintenance of the Licensed Intellectual Property. 
 (b)    In the event Licensor decides not to Prosecute and
Maintain or intends to abandon the registration or application of any rights in and to Licensed Intellectual Property, Licensor shall provide Licensee with written notice of such circumstance as promptly as practicable, including the lapse of any
such Licensed Intellectual Property, and, upon Licensee’s request, (i) Licensor shall enable Licensee to Prosecute and Maintain such registration or application, in Licensor’s name, at Licensee’s expense or (ii) Licensor
shall and hereby does irrevocably and unconditionally assign all right, title and interest in and to such Licensed Intellectual Property to Licensee (any such assigned Licensed Intellectual Property, the “Assigned IP”). Licensor
shall reasonably assist and cooperate with Licensee and its Affiliates, at Licensor’s expense, in the provision of any requested documentation necessary for the Prosecution and Maintenance of the Licensed Intellectual Property by Licensee under
this Section 7.1(b), and the execution and delivery of any other documents therefor. 

Section 7.2    Enforcement.  

(a)    Each Party shall promptly notify the other Party of any and all actual or threatened infringement, misappropriation
or other violation or misuse by any Third Party of any rights in and to the Licensed Intellectual Property (“Third Party Infringement”) which comes to such Party’s attention. 

(b)    Licensor shall enforce and protect the Licensed Intellectual Property against Third Party Infringement in
accordance with the terms and conditions of this Section 7.2(b). Upon becoming aware of any Third Party Infringement in or which could be 

  

					
		 	14	  	Intellectual Property Licence

 
reasonably expected to affect the Licensed Fields, Licensor shall promptly provide to Licensee all available information regarding such Third Party Infringement and discuss in good faith with
Licensee an appropriate course of action with respect to such Third Party Infringement and take all actions deemed necessary by Licensor with respect to such Third Party Infringement, which may include bringing a claim against the applicable Third
Party. Licensor shall have the first right (but not the obligation) to bring and control any claim of Third Party Infringement in the Licensed Fields. 

(c)    If Licensor is not pursuing a Third Party Infringement in or which could be reasonably expected to affect the
Licensed Fields, Licensee shall have the right (but not the obligation) to bring and control, and enforce with respect to, any claim or action related to such Third Party Infringement. Any recovery by Licensor or Licensee from any action or
settlement of any claim or action prosecuted by a Party under this Section 7.2(c) shall be divided amongst the Parties as follows: (i) Licensor shall receive the amount set forth in the Confidential Disclosure Letter and (ii) Licensee
shall receive the amount set forth in the Confidential Disclosure Letter, in each case, after deduction of all costs and expenses incurred by the Party pursuing the claim with respect to such claim. 

(d)    Each Party shall reasonably assist and cooperate with the Party prosecuting a claim pursuant to this
Section 7.2, at the expense of the Party prosecuting such claim, including the provision or execution of any requested documentation. Each Party acknowledges that it may be a necessary party to any claim brought by the other Party against
a Third Party arising from enforcement of the rights in and to the Licensed Intellectual Property. Unless the claim is one between only the Parties as real parties in interest, in the event that an adverse party asserts, the court rules, other Laws
then applicable provide or the prosecuting Party determines in good faith that a court lacks jurisdiction based on the other Party’s or its Affiliate’s absence as a party in such action, or if a Party is otherwise a necessary party in such
action, such Party agrees to be named as a party to such claim, at the prosecuting Party’s expense. The Parties acknowledge that the Parties have a common interest in preserving privileged communications between each Party and their
respective counsels in connection with the enforcement of any rights in and to the Licensed Intellectual Property. 

Section 7.3    Jointly Owned Intellectual Property. It is agreed and understood that the Parties will
generally follow the provisions in this Article VII with respect to Prosecution and Maintenance, as well as Third Party Infringement, of Jointly Owned Intellectual Property, except that all decisions with respect thereto will be made by mutual
agreement of the Parties and all costs and expenses with respect thereto shall be borne equally by the parties. 

Section 7.4    No Challenge. Licensee agrees that it will not challenge (or assist any Third Party in
attempting to challenge), in any country or jurisdiction, Licensor’s title to or ownership of the Licensed Intellectual Property or the validity thereof, during the Term. 

ARTICLE VIII 

INDEMNIFICATION 

Section 8.1    Licensee Indemnification Obligations. Licensee agrees to defend, indemnify and hold Licensor,
its Affiliates and each of their respective directors, officers and 

  

					
		 	15	  	Intellectual Property Licence

 
employees (the “Licensor Indemnified Parties”) harmless from and against any and all Liabilities suffered or incurred by a Licensor Indemnified Party as a result of Third Party
Claims arising from (a) Licensee’s Exploitation of the Licensed Intellectual Property, including death, injury to persons or damages to property, product liability, tort liability or any other suits, claims demands, proceedings or actions,
and (b) a breach of, or failure to satisfy, any covenant, representation, warranty or obligation of Licensee under this Agreement. The foregoing indemnity shall not apply to any Liabilities to the extent caused by or on behalf of Licensor, or
to the extent arising out of or related to Licensor’s indemnity set forth in Section 8.2. 

Section 8.2    Licensor Indemnification Obligations. Licensor agrees to defend, indemnify and hold Licensee,
its Affiliates and each of their respective directors, officers and employees (the “Licensee Indemnified Parties”) harmless from and against any and all Liabilities suffered or incurred by a Licensee Indemnified Party as a result of
Third Party Claims arising from (a) Licensor’s Exploitation of the Licensed Intellectual Property, including death, injury to persons or damages to property, product liability, tort liability or any other suits, claims demands, proceedings
or actions, and (b) a breach of, or failure to satisfy, any covenant, representation, warranty or obligation of Licensor under this Agreement. The foregoing indemnity shall not apply to any Liabilities to the extent caused by or on behalf of
Licensee, or to the extent arising out of or related to Licensee’s indemnity set forth in Section 8.1. 

Section 8.3    Indemnification Procedures. 

(a)    Any Licensor Indemnified Party or Licensee Indemnified Party that may be entitled to be indemnified under this
Agreement (an “Indemnified Party”) shall promptly notify Licensee or Licensor, as the case may be (the “Indemnifying Party”), in writing of any pending or threatened claim or demand that the Indemnified Party has
determined, has given, or would reasonably be expected to give rise to, a right of indemnification under this Agreement (a pending or threatened claim or demand asserted by a Third Party against the Indemnified Party, such claim being a
“Third Party Claim”), describing in reasonable detail the facts and circumstances with respect to the subject matter of such claim or demand; provided that the failure to provide such notice shall not release the Indemnifying Party
from any of its obligations under this Section 8.3, except to the extent the Indemnifying Party is prejudiced by such failure. 

(b)    Upon receipt of a notice of a claim for indemnity from an Indemnified Party pursuant to Section 8.3(a), the
Indemnifying Party will assume the defense and control of any Third Party Claim but shall allow the Indemnified Party a reasonable opportunity to participate in the defense of such Third Party Claim with its own counsel and at its own expense. The
Indemnified Party shall, and shall cause each of its Affiliates and representatives to, cooperate fully with the Indemnifying Party in the defense of any Third Party Claim. The Indemnifying Party shall be authorized to consent to a settlement of, or
the entry of any judgment arising from, any Third Party Claim, without the consent of the Indemnified Party; provided that the Indemnifying Party shall (i) pay or cause to be paid all amounts arising out of such settlement or judgment
concurrently with the effectiveness of such settlement, (ii) not encumber any of the material assets of any Indemnified Party or agree to any restriction or condition that would apply to or materially adversely affect any Indemnified Party or
the conduct of any Indemnified Party’s business, and (iii) obtain, as a condition of any settlement or other resolution, a complete release of any Indemnified Party potentially affected by such Third Party

  

					
		 	16	  	Intellectual Property Licence

 
Claim. In all other circumstances, neither an Indemnifying Party nor an Indemnified Party shall settle or compromise any Third Party Claim without the prior written consent of the other party,
such consent not to be unreasonably withheld, conditioned or delayed. 
 (c)    In the event any Indemnified Party
should have a claim against any Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party shall deliver notice of such claim promptly to the Indemnifying Party, describing in reasonable detail the facts giving rise to any
claim for indemnification hereunder, the amount or method of computation of the amount of such claim (if known) and such other necessary information with respect thereto as the Indemnifying Party may reasonably request. The failure to provide such
notice, however, shall not release the Indemnifying Party from any of its obligations under this Article VIII except to the extent that the Indemnifying Party is prejudiced by such failure. The Indemnifying Party shall use commercially reasonable
efforts to respond in writing within 30 days of receipt of such notice. The Indemnified Party shall reasonably cooperate and assist the Indemnifying Party in determining the validity of any claim for indemnity by the Indemnified Party and in
otherwise resolving such matters. Such assistance and cooperation shall include providing reasonable access to and copies of information, records and documents relating to such matters, furnishing employees to assist in the investigation, defense
and resolution of such matters and providing legal and business assistance with respect to such matters. If the Indemnifying Party does not so respond within such 30-day period, the Indemnifying Party shall be
deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement. 

ARTICLE IX 

CONFIDENTIALITY 

Section 9.1    Confidential Information. Each Party will: (a) use the Confidential Information of the
other Party only in accordance with the exercise of rights set forth in this Agreement and not for any other purpose; (b) not disclose the Confidential Information of the other Party to any Third Party; (c) restrict disclosure of any
Confidential Information of the other Party to those employees, agents or consultants who must be directly involved with the Confidential Information for the purposes of this Agreement and who are bound by confidentiality terms substantially similar
to those in this Agreement; (d) not reverse engineer, de-compile or disassemble any Confidential Information of the other Party other than as permitted hereunder; (e) use the same degree of care as
for its own information of like importance, but at least use reasonable care, in safeguarding against disclosure of the Confidential Information of the other Party; and (f) promptly notify the disclosing Party upon discovery of any unauthorized
use or disclosure of the Confidential Information of the disclosing Party and take reasonable steps to regain possession of such Confidential Information and prevent further unauthorized actions or other breach of this Agreement. 

Section 9.2    Exceptions to Confidentiality Obligations. Neither Party is obligated to maintain in confidence
or restrict use of Confidential Information that is: (a) published or otherwise made available to the public other than by a breach of any agreement between the Parties; (b) rightfully received by one Party from a Third Party without
confidential limitation; (c) known to the receiving Party prior to its first receipt of the same from the disclosing Party; or (d) independently developed by the receiving Party without use of any of the disclosing Party’s
Confidential Information or any breach of this Agreement. 

  

					
		 	17	  	Intellectual Property Licence

 Section 9.3    Required Disclosures. If a Party is required by
applicable Law, statute, or regulation, court order or subpoena lawfully demanding the disclosure of any Confidential Information belonging to another Party, the Party seeking to disclose the information will, to the extent not prohibited by
applicable Law, give to the other Party prompt written notice of the request and a reasonable opportunity to object to such disclosure and seek a protective order or appropriate remedy. If, in the absence of a protective order or other remedy, the
Party seeking to disclose Confidential Information belonging to the other Party determines, upon the advice of counsel, that it is required to disclose such information, it may disclose the other Party’s Confidential Information only to the
extent compelled to do so. 
 Section 9.4    Publicity. Neither Party shall make any press release or other
public statement or disclosure (including communications to employees, customers or suppliers) regarding this Agreement, its contents or the transactions contemplated hereby without giving the other Party reasonable prior notice thereof and the
opportunity to review and comment upon such release, statement or disclosure, unless and only to the extent that disclosure is required under applicable Law. 

ARTICLE X 
 MISCELLANEOUS

 Section 10.1    Section 365(n) of the Bankruptcy Code. All rights and licenses granted under this
Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section
101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. 

Section 10.2    Fees and Expenses. Except as otherwise provided herein, all fees and expenses incurred in
connection with or related to this Agreement and the transactions contemplated hereby and thereby shall be paid by the Party incurring such fees or expenses, whether or not such transactions are consummated. 

Section 10.3    Amendment and Modification. This Agreement may not be amended, modified or supplemented in any
manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each Party. 

Section 10.4    Waiver. No failure or delay of any Party in exercising any right or remedy hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof
or the exercise of any other right or power. Any agreement on the part of any Party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such Party. 

  

					
		 	18	  	Intellectual Property Licence

 Section 10.5    Notices. All notices and other communications
hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, or if by e-mail, upon written confirmation of receipt by
e-mail or otherwise, (b) on the first Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier, (c) on the date sent by facsimile (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of
the recipient or (d) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered
to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the Party to receive such notice: 
  

	 	(i)	if to Licensor, to: 

 Hologic, Inc. 

10210 Genetic Center Drive 
 San
Diego, CA 92121 
 Attention: Legal Department 

E-mail: dru.greenhalgh@hologic.com 

with a copy (which shall not constitute notice) to: 

Gibson, Dunn & Crutcher LLP 

200 Park Avenue 
 New York, NY
10166-0193 
 Attention: Barbara Becker 

E-mail: bbecker@gibsondunn.com 

 

	 	(ii)	if to Licensee, to: 

 Grifols Diagnostic Solutions Inc. 

Avinguda de la Generalitat, 152-158 

Parc de Negocis Can Sant Joan 

Sant Cugat del Valles 08174 

Barcelona, Spain 
 Facsimile:
+34.93.571.0267 
 Attention: Alfredo Arroyo 

E-mail: Alfredo.Arroyo@grifols.com 

with a copy (which shall not constitute notice) to: 

Osborne Clarke S.L.P. 
 Avenida
Diagonal, 477 
 Planta 20 

08036 Barcelona Spain 

Facsimile: +34.93.410.2513 

Attention: Tomás Dagá 

Email: Tomas.Daga@osborneclarke.com 

  

					
		 	19	  	Intellectual Property Licence

 and 

Proskauer Rose LLP 
 Eleven
Times Square 
 New York, New York 10036 

Facsimile: +1 (212) 969-2900 

Attention: Peter G. Samuels 

         Daryn A. Grossman 

Email: PSamuels@proskauer.com 

            DGrossman@proskauer.com 

Section 10.6    Interpretation. When a reference is made in this Agreement to a Section or Article such
reference shall be to a Section or Article of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement are for convenience of reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in the Confidential Disclosure Letter but not otherwise defined therein
shall have the meaning as defined in this Agreement. The Confidential Disclosure Letter is hereby incorporated in and made a part of this Agreement as if set forth herein. The word “including” and words of similar import when used in this
Agreement will mean “including, without limitation,” unless otherwise specified. The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to the
Agreement as a whole and not to any particular provision in this Agreement. The term “or” is not exclusive. The word “will” shall be construed to have the same meaning and effect as the word “shall.” References to days
mean calendar days unless otherwise specified. 
 Section 10.7    Entire Agreement. This Agreement
(including the Confidential Disclosure Letter), together with the Purchase Agreement and any agreements required by the Purchase Agreement, constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and
understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings between the Parties with respect to the subject matter hereof and thereof. 

Section 10.8    Third-Party Beneficiaries. This Agreement shall be binding upon and inure solely to the
benefit of each Party, and nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the Parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of
any nature whatsoever under or by reason of this Agreement, except with respect to the provisions of Article VIII, which shall inure to the benefit of the Persons benefiting therefrom who are intended to be third-party beneficiaries thereof.

 Section 10.9    Governing Law. This Agreement and all disputes or controversies arising out of or
relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to the laws of any other jurisdiction that might be applied because
of the conflicts of laws principles of the State of New York. 

  

					
		 	20	  	Intellectual Property Licence

 Section 10.10    Submission to Jurisdiction. The sole
jurisdiction, venue and dispute resolution procedure for all disputes, controversies or claims (whether in contract, tort or otherwise) arising out of, relating to or otherwise by virtue of, this Agreement, breach of this Agreement or the
transactions contemplated by this Agreement shall be the federal and state courts located within the Borough of Manhattan in New York, New York, and the Parties hereby consent to the jurisdiction of such court and waive any objection to the venue of
such proceeding. Each of the Parties agrees that process may be served upon it in the manner specified in Section 10.5 and irrevocably waives and covenants not to assert or plead any objection which it might otherwise have to such jurisdiction,
or to such manner of service of process. 
 Section 10.11    Personal Liability. This Agreement shall not
create or be deemed to create or permit any personal liability or obligation on the part of any direct or indirect equityholder of Licensor or Licensee or any officer, director, employee, representative or investor of any Party. 

Section 10.12    Assignment; Successors. Neither Party shall assign this Agreement by operation of Law or
otherwise without the prior written consent of other Party, except that (a) a Party may assign all or a portion of its rights and obligations under this Agreement to any of its Affiliates, and (b) a Party may assign all or a portion of its
rights and obligations under this Agreement in connection with a sale or disposition of any assets, entities or lines of the business of such Party or any of its Affiliates to which this Agreement relates; provided, that in the case of this clause
(b), the transferee of such assets, entities or lines of the business shall be bound by the terms of this Agreement as if named as a “Party” hereto; provided, further, that no such assignment shall release the assigning Party from any
liability or obligation under this Agreement prior to the date of such assignment. Notwithstanding anything in this Section 10.12, Licensor shall be permitted to make any pledge or collateral assignment of this Agreement or any of its rights
hereunder to any of its collateral agents, administrative agents and/or lenders; provided that (i) no such assignment shall relieve Licensor of its obligations hereunder and (ii) such assignment shall not in any way limit any of the rights
granted to Licensee hereunder. Any attempted assignment in violation of this Section 10.12 shall be void. This Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by the Parties and their permitted
successors and assigns. 
 Section 10.13    Enforcement. The Parties agree that irreparable damage would
occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the Parties shall be entitled to specific performance of the terms hereof,
including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the federal and state courts located within the Borough of Manhattan in New York, New York, this
being in addition to any other remedy to which such Party is entitled at law or in equity. Each of the Parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any
requirement under any law to post security as a prerequisite to obtaining equitable relief. 

  

					
		 	21	  	Intellectual Property Licence

 Section 10.14    Severability. Whenever possible, each provision
or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed,
construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein. 

Section 10.15    Waiver of Jury Trial. EXCEPT AS LIMITED BY APPLICABLE LAW, EACH PARTY HERETO HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. 
 Section 10.16    Counterparts. This Agreement may be
executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties. 

Section 10.17    Facsimile or .pdf Signature. This Agreement may be executed by facsimile or .pdf signature
and a facsimile or .pdf signature shall constitute an original for all purposes. 
 Section 10.18    No
Presumption Against Drafting Party. Each Party acknowledges that each Party to this Agreement has been represented by legal counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of
law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting Party has no application and is expressly waived. 

The remainder of this page is intentionally left blank. 

  

					
		 	22	  	Intellectual Property Licence

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective
Date by their respective officers thereunto duly authorized. 
  

			
	HOLOGIC, INC.
		
	By:	 	 /s/ John M. Griffin

	Name:	 	John M. Griffin
	Title:	 	General Counsel
	
	GEN-PROBE INCORPORATED
		
	By:	 	 /s/ John M. Griffin

	Name:	 	John M. Griffin
	Title:	 	President
	
	GRIFOLS DIAGNOSTIC SOLUTIONS INC.
		
	By:	 	 /s/ Carsten Schroeder

	Name:	 	Carsten Schroeder
	Title:	 	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]